Australija - anglų - APVMA (Australian Pesticides and Veterinary Medicines Authority)

syngenta australia pty ltd - thiamethoxam - water dispersible granule - thiamethoxam thiazole active 250.0 g/kg - insecticide - turf and lawn - african black beetle - 1st instar larvae | argentinian scarab - first instar larvae | bill bug - larvae | billbug | la plata weevil

Izraelis - anglų - Ministry of Health

novartis israel ltd - ranibizumab - solution for injection - ranibizumab 10 mg/ml - ranibizumab - ranibizumab - treatment of patients with neovascular (wet) age-related macular degeneration (amd). treatment of adult patients with visual impairment due to diabetic macular oedema (dme) . the treatment of visual impairement due to macular oedema secondary to retinal vein occlusion (rvo). the treatment of visual impaiment due to choroidal neovascularization (cnv) . lucentis is indicated in preterm infants for: the treatment of retinopathy of prematurity (rop) with zone i (stage 1+, 2+, 3 or 3+), zone ii (stage 3+) or ap-rop (aggressive posterior rop) disease.the treatment of proliferative diabetic retinopathy (pdr)

Europos Sąjunga - anglų - EMA (European Medicines Agency)

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - eylea is indicated for adults for the treatment of:neovascular (wet) age-related macular degeneration (amd);visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo);visual impairment due to diabetic macular oedema (dme);visual impairment due to myopic choroidal neovascularisation (myopic cnv).

Australija - anglų - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ranibizumab, quantity: 1.65 mg - injection, solution - excipient ingredients: histidine; histidine hydrochloride monohydrate; trehalose dihydrate; polysorbate 20; water for injections - lucentis (ranibizumab) is indicated in adults for:,- the treatment of neovascular (wet) age-related macular degeneration (amd),- the treatment of visual impairment due to diabetic macular oedema (dme),- the treatment of proliferative diabetic retinopathy (pdr),- the treatment of visual impairment due to choroidal neovascularisation.,- the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm),- the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo)

Australija - anglų - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ranibizumab, quantity: 2.3 mg - injection, solution - excipient ingredients: histidine; histidine hydrochloride monohydrate; trehalose dihydrate; polysorbate 20; water for injections - lucentis (ranibizumab) is indicated in adults for:,? the treatment of neovascular (wet) age-related macular degeneration (amd), ? the treatment of visual impairment due to diabetic macular oedema (dme), ? treatment of proliferative diabetic retinopathy (pdr), ? the treatment of visual impairment due to choroidal neovascularisation, ? the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm), ? the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo).,lucentis is indicated in preterm infants for:,? the treatment of retinopathy of prematurity (rop) with zone i (stage 1+, 2+, 3 or 3+), zone ii (stage 3+) or ap-rop (aggressive posterior rop) disease.

Izraelis - anglų - Ministry of Health

bayer israel ltd - aflibercept - solution for intravitreal injection - aflibercept 40 mg/ml - aflibercept - eylea is indicated for adults for the treatment of • neovascular (wet) age-related macular degeneration (amd)• visual impairment due to macular oedema secondary to retinal vein occlusion (branch crvo or central rvo)• visual impairment due to diabetic macular oedema (dme)• visual impairment due to myopic choroidal neovascularisation (myopic cnv).

Singapūras - anglų - HSA (Health Sciences Authority)

meridian impetus holdings pte. ltd. - physical medicine - the device is indicated for knee osteoarthritis. the pain of mild and moderate knee osteoarthritis can be alleviated and improved to some degree.

Singapūras - anglų - HSA (Health Sciences Authority)

all eights (singapore) private limited - microbiology - immunocard stat! ehec is an immunochromatographic rapid test for the qualitative detection of shiga toxins 1 and 2 (also called verotoxins) produced by e.coli in cultures derived from clinical stool specimens. immunocard stat! ehec is used in conjunction with the patient’s clinical symptoms and other laboratory tests to aid in the diagnosis of diseases caused by enterohemorrhagic e. coli (ehec) infections.

Singapūras - anglų - HSA (Health Sciences Authority)

mandarin opto-medic co pte ltd - ophthalmology - the endoprobes direct the laser energy from the laser unit to which they are connected, by means of total reflection to the desired treatment site. they are designed for intraocular, transscleral and panretinal treatment for the indication of the ophthalmologist to use.

Singapūras - anglų - HSA (Health Sciences Authority)

all eights (singapore) private limited - clinical chemistry - the illumigene c.difficile dna amplification assay, performed on the illumipro-10, is a qualitative in vitro diagnostic test for the direct detection of toxigenic c.difficile in human stool specimens from patients suspected of having clostridium difficile-associated disease (cdad). illumigene c. difficile is intended for use in hospital , reference or state laboratory settings. the device is not intended for point-of-care use.